At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study of Oral IXAZOMIB (MLN9708) to Assess Relative Bioavailability, Food Effect, Drug-Drug Interaction With Ketoconazole, Clarithromycin or Rifampin; and Safety and Tolerability in Patients With Advanced Nonhematologic Malignancies or Lymphoma
In Brief
A Phase 1 clinical trial evaluating Ixazomib 2.5 mg, Ixazomib 4 mg Capsule A, and 4 other interventions for Nonhematologic Malignancies and Lymphoma. Completed, enrolled 112 participants across 1 site.
Detailed Summary
This is an open-label, multicenter, sequential, 5-arm, phase 1 study of oral IXAZOMIB designed to assess drug-drug interaction with ketoconazole (Arm 1), the relative bioavailability of 2 capsule formulations of IXAZOMIB (Arm 2), food effect (Arm 3), drug-drug interaction with rifampin (Arm 4), and drug-drug interaction with clarithromycin (Arm 5) in participants with advanced nonhematologic malignancies or lymphoma.
Study Details
Timeline
Interventions
Ixazomib 2.5 mg Capsule B (Cycle 1 only)
Ixazomib 4 mg Capsule A (Cycle 1 only)
Ixazomib 4 mg Capsule B (Cycle 2 and beyond )
Ketoconazole 400 mg tablets (Cycle 1 only)
Rifampin 600 mg capsule (Cycle 1 only)
Clarithromycin 500 mg tablets (Cycle 1 only)
Ixazomib 4 mg Capsule B (Cycle 1 and beyond)